Eli Lilly and Company (NYSE:LLY) Stock Rating Lowered by Wall Street Zen

Eli Lilly and Company (NYSE:LLY) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Monday.

Other research analysts also recently issued research reports about the company. Bank of America raised their price objective on Eli Lilly and Company from $1,293.00 to $1,294.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price objective for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Leerink Partners raised their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a research note on Thursday, February 5th. Rothschild & Co Redburn raised their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research note on Monday, January 26th. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,222.22.

Eli Lilly and Company Stock Up 0.3%

Eli Lilly and Company stock opened at $930.08 on Monday. The stock has a market cap of $878.76 billion, a PE ratio of 40.53, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The stock has a fifty day moving average of $988.75 and a 200 day moving average of $973.25.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the prior year, the business posted $5.32 earnings per share. The business’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its stake in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the period. Evolution Wealth Management Inc. bought a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $29,000. Finally, Steph & Co. raised its stake in Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after purchasing an additional 29 shares during the period. Institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval of Foundayo creates a new high?value product opportunity that could add billions to sales and validate Lilly’s oral GLP?1 strategy. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: CEO Dave Ricks says Lilly is ready to scale production of Foundayo, reducing execution risk and supporting faster commercialization. Eli Lilly CEO Says Company Ready to Scale Production
• Positive Sentiment: Lilly will manufacture the GLP?1 at a new Houston facility, supporting supply and limiting bottlenecks as demand ramps. Lilly’s $6.5B Houston plant will make its new FDA-approved GLP-1
• Positive Sentiment: Brokerage reaction includes modest price?target increases and renewed analyst attention, reflecting confidence in Foundayo’s sales potential despite valuation questions. Price Target Raised Following FDA Approval
• Neutral Sentiment: Lilly amended its collaboration with AC Immune to advance next?generation Tau aggregation inhibitors with IND?enabling studies planned in 2026 — diversification into neurodegeneration could be material longer term but won’t move near?term revenue. Eli Lilly Extends AC Immune Tau Pact
• Negative Sentiment: Pricing pressure: Novo Nordisk launched a lower?priced Wegovy HD at about a 40% lower cash price than Lilly’s offering, raising concerns that price competition could blunt Foundayo’s revenue and margins. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Market commentary flags a broader GLP?1 price war and side?effect/competition concerns that have driven short?term profit?taking and tempered the stock’s post?approval rally. Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.